Reading size

PACK IN HAND · ONE-PAGE CHECK

Medicine pack check sheet

Print this sheet or fill it in before speaking with a pharmacist or clinician. Copy only what is printed on the pack in hand. The published fields below are starting points from this record, not proof that your pack is the same product.

Published record starting point

Record display name
Exelon Patch
Generic name / active ingredient
rivastigmine transdermal system
Dosage-form class
Rivastigmine transdermal delivery systems (patches): 4.6 mg/24 h, 9.5 mg/24 h and 13.3 mg/24 h nominal delivery (as listed in the current U.S. label)
Route
Transdermal
Record reviewed
2026-08-19

Copy from the pack in hand

Source-linked reading points

  • Total amount in the patch is not the nominal amount delivered over 24 hours: the 9.5 mg/24h system contains 18 mg total rivastigmine base and has an area of 10 cm². Check mg/24h, total content, area, NDC and market together.
  • The label identifies failure to remove an old patch and use of multiple patches as sources of serious medication errors. A caregiver record should separately confirm ‘old patch removed’ and ‘new patch applied’. If duplicate patches are found, do not calculate a remedy online; use local clinician, poison-control or urgent-care routes.
  • Do not cut, fold, damage or alter a patch to obtain a ‘half amount’; a damaged pouch or patch is not the same as an intact product. Handling needs the current label for the exact product and pharmacist review.
  • The label warns against prolonged exposure to external heat. This page only flags questions about heating pads, saunas, strong sun and other heat exposure; it does not decide whether an individual exposure is safe or generate an application-site or duration plan.

Reviewed presentation examples — compare every field

  • 4.6 mg/24h nominal delivery; 9 mg total in the system; 5 cm²NDC 0078-0501-15
  • 9.5 mg/24h nominal delivery; 18 mg total in the system; 10 cm²NDC 0078-0502-15
  • 13.3 mg/24h nominal delivery; 27 mg total in the system; 15 cm²NDC 0078-0503-15

EDITORIAL RECORD

Who prepared and checked this page

Byline
OriginDrug Content Editorial
Review role
Public primary-source verification
Last reviewed
2026-08-19
Source record
3 clickable primary-source entry points are listed with this dossier.

The review role checks source traceability, stated market, document version and product-identity fields. It is not a claim of clinical licensure, prescribing authority or individual pharmacy service. Read the editorial policy.

Search records
Enlarged public-label image